Death risk higher with mental illness in drug trials

August 30, 2013
Death risk higher with mental illness in drug trials
Adults with psychiatric illnesses such as schizophrenia, depression, and bipolar disorder who participate in clinical trials of psychopharmacological drugs have a higher mortality risk, in many cases by suicide, according to a study published online Aug. 28 in JAMA Psychiatry.

(HealthDay)—Adults with psychiatric illnesses such as schizophrenia, depression, and bipolar disorder who participate in clinical trials of psychopharmacological drugs have a higher mortality risk, in many cases by suicide, according to a study published online Aug. 28 in JAMA Psychiatry.

Arif Khan, M.D., from the Northwest Clinical Research Center in Bellevue, Washington, and colleagues analyzed for 92,542 patients with from the U.S. Food and Drug Administration Summary Basis of Approval reports for 28 psychopharmacological agents approved between 1990 and 2011.

The researchers found that, compared with the general population, the risk of mortality was 3.8-fold higher in patients with schizophrenia, 3.15-fold higher in patients with depression, and 3.0-fold higher in patients with bipolar disorder. Death was due to suicide in 41.1 percent of 265 cases. Assignment to psychotropic agents rather than placebo did not increase , with the exception of heterocyclic antidepressants.

"These data suggest that increased mortality rates reported in population studies are detectable among adult patients with psychiatric illnesses participating in psychopharmacological trials," Khan and colleagues conclude.

Arif Khan founded Columbia Northwest Pharmaceuticals.

Explore further: Community treatment of psych patients tied to less mortality

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Community treatment of psych patients tied to less mortality

November 13, 2012

(HealthDay)—For patients with psychiatric disorders, community treatment orders correlate with a reduction in mortality, according to research published online Nov. 12 in CMAJ, the journal of the Canadian Medical Association.

Mortality similar for single and multiple primary melanomas

June 24, 2013

(HealthDay)—Mortality is similar for patients with single primary melanomas (SPMs) and multiple primary melanomas (MPMs), but relative mortality is considerably higher for patients with thicker SPMs versus thicker MPMs, ...

Recommended for you

Is neuroticism fueled by overthinking?

August 27, 2015

Isaac Newton was a classic neurotic. He was a brooder and a worrier, prone to dwelling on the scientific problems before him as well as his childhood sins. But Newton also had creative breakthroughs—thoughts on physics ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.